The National Comprehensive Cancer Network (NCCN) suggests that all ovarian cancer patients, regardless of family history, should be considered for BRCA1/BRCA2 gene testing [22], whereas the European Society for Medical Oncology (ESMO) suggests that they should be considered according to a family history of breast and ovarian cancer [23]. The gene discussed is BRCA1; the disease is ovarian cancer.